Qual é o preço para GlycoNex Incorporation (4168)

O preço para GlycoNex Incorporation (4168) é $0.71865803

Qual é a capitalização de mercado para GlycoNex Incorporation (4168)

A capitalização de mercado para GlycoNex Incorporation (4168) é $80.86M

GlycoNex Incorporation (4168) Margem Operacional

GlycoNex Incorporation, based in New Taipei City, Taiwan, specializes in developing innovative cancer therapeutics. The company achieves this by leveraging advanced glycosphingolipid antigen and human monoclonal antibody technologies. Its robust pipeline for solid tumors features several investigational antibody drugs. These include GNX102, a humanized monoclonal antibody currently in Phase 1 clinical trials; GNX201, an antibody candidate undergoing lead optimization; and GNX202, which is in preclinical development. Additionally, GNX203 and GNX204 are antibody drugs presently in the target validation stage. Beyond oncology, GlycoNex is also advancing other therapeutic agents. This includes SPD (Denosumab), a humanized IgG2 antibody in preclinical stages for both osteoporosis and oncology indications. Another key asset is SEA (Aflibercept), a vascular endothelial growth factor (VEGF) binding fusion protein, currently undergoing lead optimization for its potential use in ophthalmology and oncology. GlycoNex was established in 2001.

Ano	Margem Operacional	Alterar
Não há dados suficientes para as datas fornecidas.

Ano

Margem Operacional

Alterar

Não há dados suficientes para as datas fornecidas.

Empresa	Margem Operacional	Diferença na Margem Operacional	País
Vertex Pharmaceuticals Incorporated VRTX.US	38.59%	-	US
Argenx SE ARGX.US	28.81%	-	NL
Moderna, Inc. MRNA.US	-149.01%	-	US
CSL Limited CSL.AX	25.72%	-	AU
Lonza Group AG LONN.SW	0.00%	-	CH

Empresa

Margem Operacional

Diferença na Margem Operacional

País